Liquid Chromatograph-Mass Spectrometry
LC/MS is becoming nowadays a routine tool in many application fields. It provides a solution with high selectivity, reliability, productivity and sensitivity requested in the areas of pharmaceuticals, food safety, chemicals, environmental analysis, as well as clinical. Shimadzu is offering a complete range from single quadrupole system, triple quadrupole systems to High Resolution MS system.
Shimadzu's LC/MS (Liquid Chromatograph-Mass Spectrometry) systems have created a new trend in the LCMS world, associating very fast polarity switching to fast scanning, low dwell time and pause time, while increasing sensitivity and data quality. This results in a powerful range enabling more compounds to be screened in less runs. It enables qualitative and quantitative analysis and, in fine, improves return of investment for all laboratories.
Time of Flight Instruments (Q-TOF)
LCMS-9030
Triple Quadrupole LC-MS/MS Instruments
LCMS-8060NX
LCMS-8060
LCMS-8050
LCMS-8045
LCMS-8040
Single Quadrupole LCMS Instruments
LCMS-2020
DPiMS-2020
Single Quad Preparative LCMS
LCMS Medical Devices
LCMS In Vitro Diagnostic (IVD) Medical Devices
Solutions/Accessories for LCMS TQ & HRMS
CLAM - 2030
C2MAP System
Direct Probe Ionization Mass Spectrometer Kit
Nexera MX
Nexera Mikros
LDTD™ Ion Source Option for LCMS-8050/8060
Trap-Free 2D LC/MS sytem for Quadrupole LCMS
DPiMS™ QT
LC-MS Columns & Consumables
Software
LabSolutions Insight Library Screening
Solution System Packages
Sample preparation tools
LC-MS webinars
LC-MS Method Development Part 1: Differences from LC
This webinar is designed for people who are new to LC-MS/MS to give them a grounding in the differences from LC before moving onto more in-depth discussions about method development.
LC-MS Method Development Part 2
This second session will cover the objectives and strategies to use for successful LC-MS(MS) method development. For beginners, we suggest you watch Session 1 before attending this session.
Simultaneous Analysis of COVID-19 Drug Candidates in Human Plasma by LC-MS/MS
In 2019, the COVID19 caught the world almost by surprise. Its relentless spread over the world forced authorities to act rapidly to find an adequate treatment. Besides drastic measure taken to lockdown half world population, some drugs targeting single strand RNA viruses, Malaria or even bacterials stains were propelled to FDA fast track of testing and approval to fight this new threat. Lacking deep phase I-II studies, clinical centers and hospitals had to set their own protocol to administer the treatment. Since many bioanalytical labs were equipped with LCMS/MS, corresponding stable isotope labeled standards availability became critical to monitor the drugs. We report here the analytical method developed by Alsachim using the molecules synthesized at our facilities.